Diabesity Rounds

Trevogrumab reduced lean mass loss on semaglutide in phase 2 trial

In COURAGE, trevogrumab reduced lean mass loss at 75 mg and above; 25 mg was not significant. Adding garetosmab improved body composition further, but safety and tolerability were not favourable.

At a glance

  • Lean mass fell at week 26 with semaglutide plus placebo (-6.6%). Trevogrumab 200 mg or 400 mg reduced this loss, and trevogrumab 400 mg plus garetosmab reduced it most.
  • Trevogrumab alone was generally well tolerated. The garetosmab combination had a high incidence of serious adverse events (14 [9%] of 149) and discontinuations (48 [32%] of 149). Both deaths in the study were in this group, with no causal link identified.
  • The abstract does not report physical function outcomes. The authors say further study is needed to learn whether better body composition preserves function and metabolic health.

Key result

All three antibody regimens lessened lean mass loss versus semaglutide plus placebo at 26 weeks.

Lean mass % change, difference vs semaglutide+placebo, Week 26 (part A) (percentage points)

trevogrumab 200 mg3.1
trevogrumab 400 mg2.7
trevogrumab 400 mg+garetosmab4.5

605 participants · 26 weeks · 95% CIs exclude zero

Numbers as reported in the source.

The study

COURAGE is a two-part, phase 2, double-blind, placebo-controlled, randomised trial published in the Lancet. It was run at 60 sites in the US. It enrolled 975 adults aged 18-80 years with obesity (BMI 30 kg/m2 or more). Mean age was 49.0 years and mean BMI was 36.7 kg/m2. Of the participants, 627 (64%) were female. Regeneron Pharmaceuticals, Inc. funded the study.

In part A (26 weeks, n=605), participants received semaglutide titrated to 2.4 mg subcutaneously weekly. They were also assigned to placebo, trevogrumab (anti-GDF8) 200 mg, trevogrumab 400 mg, or trevogrumab 400 mg plus garetosmab (anti-activin A) 10 mg/kg. Part A also had a semaglutide withdrawal period. In part B (n=376), participants received semaglutide for 52 weeks. They were assigned to placebo, trevogrumab 25 mg or trevogrumab 75 mg. The primary endpoints were percent change in lean mass, fat mass and bodyweight.

What they found

Lean mass, part A. With semaglutide plus placebo, lean mass fell at week 26 (-6.6%, 95% CI -7.4 to -5.7). The estimated treatment differences versus placebo were +3.1% (1.9 to 4.3) for trevogrumab 200 mg, +2.7% (1.5 to 4.0) for trevogrumab 400 mg, and +4.5% (3.1 to 5.9) for trevogrumab 400 mg plus garetosmab.

Lean mass, part B. With placebo, lean mass fell at week 52 (-7.3%, -8.8 to -5.8). The estimated treatment difference was +1.5% (-0.3 to 3.3) with trevogrumab 25 mg and +3.1% (1.3 to 4.9) with trevogrumab 75 mg. The 25 mg result was not significantly different from placebo, because the confidence interval included zero.

Fat mass and weight. In part A, fat mass fell with placebo (-15.6%). The estimated treatment difference was significant for trevogrumab 400 mg (-3.4%) and for the combination (-11.7%). Bodyweight fell with placebo (-10.6%). The estimated treatment difference was significant only for the combination (-2.7). No other groups in part A, and none in part B, were significantly different from placebo for fat mass or bodyweight.

Safety. Semaglutide plus trevogrumab alone was generally well tolerated, with a safety profile similar to semaglutide plus placebo. The combination group had a high incidence of serious adverse events, in 14 (9%) of 149 participants, and of discontinuations, in 48 (32%) of 149. Muscle spasms occurred in 61 (41%) of 149 in the combination group, 23 (8%) of 299 in the trevogrumab 200 mg and 400 mg groups, and seven (5%) of 151 in the placebo group. Two deaths occurred, both in the combination group. The abstract says a causal association with treatment was not identified.

How much weight to give it

The authors call this a proof of concept for GDF8 inhibition with trevogrumab alone. They say the combination did not have favourable safety and tolerability. The trial is large, randomised, double-blind and placebo-controlled. The main limits are these.

  • Lean mass, fat mass and bodyweight are surrogate outcomes. The abstract does not report strength, physical function or other clinical outcomes.
  • The abstract does not report how lean mass was measured. It also does not report the results of the withdrawal period or the MRI thigh substudy.
  • The trial was US-based. The abstract does not report results by ethnicity.
  • Serious adverse event and discontinuation rates are given in the abstract only for the combination group, so they cannot be compared with the other groups. Two deaths occurred, both in the combination group; a causal association between treatment and these events was not identified.

For your clinic

The abstract describes pronounced muscle loss with GLP-1 receptor agonist weight loss, and this trial suggests trevogrumab may reduce the loss of lean mass. Whether that helps patients in daily life is not yet shown. The authors themselves say further study is needed. Read the full paper for the body composition methods, the adverse event tables and the safety details of the combination before drawing any conclusion. Wait for trials with functional outcomes.

Source

Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.

Mosenzon O, Rosenstock J, Raya JG et al.. Lancet (London, England). 11 November 2026

Read the source · DOI 10.1016/S0140-6736(26)01953-7

Cite this report: Diabesity Rounds. Trevogrumab reduced lean mass loss on semaglutide in phase 2 trial. 2026. doi:10.5281/zenodo.24236981

Teaching a session? Download this report as a slide (PNG, free to use with credit).

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on obesity medicine

Go deeper